Why the study?
Because of a paucity of good quality data, the optimal anticoagulation strategy for stroke prevention in patients with rheumatic mitral stenosis and AF is not known.
What is the optimal oral anticoagulation strategy for stroke prevention in patients with rheumatic mitral stenosis and atrial fibrillation?
What is the optimal oral anticoagulation strategy for stroke prevention in patients with rheumatic mitral stenosis and atrial fibrillation?
There is a paucity of good quality data regarding the optimal anticoagulation strategy for stroke prevention in patients with rheumatic mitral stenosis and atrial fibrillation.
Optimal anticoagulation for stroke prevention in MS with AF and RHD remains unknown; leaves open dedicated trials.
heumatic heart disease (RHD) is an important cause of stroke in low-and middle-income countries. About 80% of the strokes in patients with RHD occur in patients with mitral stenosis (MS) and atrial fibrillation (AF). The pathophysiology and risk markers of stroke in patients with MS and AF are well recognized, but because of a paucity of good quality data, the optimal anticoagulation strategy for stroke prevention in these patients is not known.
No takes yet. Share an insight, caveat, or question.
Karthikeyan et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: